Estimating the Benefit of an HIV-1 Vaccine That Reduces Viral Load Set Point

Vaccines designed to induce cell-mediated immune responses against human immunodeficiency virus (HIV)-1 are being developed. Such vaccines are unlikely to provide sterilizing immunity but may be associated with reduced viral set points after infection. We modeled the potential impact of a vaccine th...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2007-02, Vol.195 (4), p.546-550
Main Authors: Gupta, Swati B., Jacobson, Lisa P., Margolick, Joseph B., Rinaldo, Charles R., Phair, John P., Jamieson, Beth D., Mehrotra, Devan V., Robertson, Michael N., Straus, Walter L.
Format: Article
Language:English
Subjects:
AIDS
AIDS Vaccines - immunology
Antiretrovirals
Applied microbiology
Biological and medical sciences
Cohort Studies
Disease Progression
Fundamental and applied biological sciences. Psychology
HIV
HIV 1
HIV Infections - immunology
HIV Infections - therapy
HIV Infections - virology
HIV-1 - immunology
HIV-1 - physiology
HIV/AIDS
Humans
Infections
Infectious diseases
Male
Medical sciences
Microbiology
Miscellaneous
Regression Analysis
RNA
T lymphocytes
Time Factors
Vaccination
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Viral Load
Virology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vaccines designed to induce cell-mediated immune responses against human immunodeficiency virus (HIV)-1 are being developed. Such vaccines are unlikely to provide sterilizing immunity but may be associated with reduced viral set points after infection. We modeled the potential impact of a vaccine that reduces viral set point after infection, using natural history data from 311 HIV-1 seroconverters. Log-normal parametric regression models were used to estimate the log median time to events of interest. Relative times were estimated for those with viral load set points of 30,000 copies/mL (reference group) versus those with lower viral set points. The time to key clinical events in the course of HIV-1 disease progression was significantly extended for those with viral set points 0.5–1.25 log10 copies/mL lower than the reference group. By quantifying the anticipated clinical benefits associated with a reduction in viral set point, these findings support the use of virologic end points in HIV-1 vaccine trials.
ISSN:0022-1899
1537-6613
DOI:10.1086/510909